AUL
NRIX icon

AlphaGrep UK Ltd’s Nurix Therapeutics NRIX Stock Holding History

AlphaGrep UK Ltd’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Buy
+19,096
New +$317K 0.09% 517

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

AlphaGrep UK Ltd's NRIX Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 19,096 shares worth $296K. The stake represents 0.09% of the portfolio and ranks #517 among its holdings.

196 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • AlphaGrep UK Ltd held 19,096 shares of Nurix Therapeutics worth $296K as of Q1 2026.
  • Nurix Therapeutics was a new AlphaGrep UK Ltd position in Q1 2026.
  • Nurix Therapeutics made up 0.09% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #517 holding.
  • 196 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.